As part of the agreement, the two companies are developing joint operations and technology-transfer protocols and will implement an integrated approach to bring complex controlled-release products to market faster and more efficiently with optimal therapeutic and release profiles, reports Pharmabiz.
Catalent’s analytical/CMC, solid-state optimisation, clinical and commercial supply services along with Bend’s formulation development expertise will supply pharmaceutical companies with dosage forms and path to market.
Bend Research CEO Rod Ray was quoted by the news agency as saying that the company’s integrated approach is geared toward complex, multiparticulate controlled-release products, which traditionally have presented a high scale-up risk when they are transferred to commercial manufacturing sites.
”We believe that Catalent’s breadth of services and demonstrated success in bringing controlled-release products to market, as well as supplying them globally, makes them an ideal complement to our development strengths," Ray added.
Catalent President Ian Muir said, "Catalent and Bend are aligning their scientific expertise and processes to ensure that developments are undertaken from Day One based on Quality by Design principles.”